Target Inhibition and Silencing: "Hits to Lead" Advances in Clinical and Translational Research

In this initiative of the Harvard Catalyst Translational Innovator Program, in partnership with the ICCB-Longwood Screening Facility, the community was invited to develop proposals that apply the high-throughput laboratory automation, or small molecule or siRNA library screening capabilities of ICCB-Longwood to problems of clinical and translational importance as they pertain to human health. Applications were required to focus on human specimens or human disease in areas such as infectious disease or biodefense, therapeutic targets, emerging human disease pathways, gene knockdown and functional genomics, or target silencing and inhibition.

Funding Decisions were announced in December 2014

Sponsoring Program

Translational Innovator


Donald Coen, PhD | Discovery of Small Molecules to Inhibit Human Cytomegalovirus Nuclear Egress
Jeffrey D. Dvorin, MD, PhD | Novel Gene Discovery in Plasmodium falciparum Malaria
Christopher A. French, MD | Targeted Inhibition of BRD-NUT Oncoproteins 
Alfred Goldberg, PhD | Screening for Inhibitors of the Proteolytic Complex ClpXP1P2 from M. tuberculosis
Elizabeth Henske, MD | Metabolic Targeting of Tumor Cells with Hyperactive TORC1
James E. Kirby, MD | Plasmid Eviction to Restore Susceptibility in Carbapenem-Resistant Enterobacteriaceae
Ralph Scully, MB BS, PhD | High Throughput Screen for siRNA Modulators of Non-homologous End Joining
Priscilla Yang, PhD | High Throughput Screening to Identify Inhibitors of Dengue Virus (DV) Entry